---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-003153"
form_type: "8-K"
ticker: "TTRX"
cik: "0002023016"
company_name: "Turn Therapeutics Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:58:27.365424+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Turn Therapeutics provides pipeline update; GX-03 Phase 2 data expected H1 2026, appoints Martin Dewhurst to board

## Summary
- Phase 2 trial of GX-03 for moderate-severe atopic dermatitis on track; interim and topline data expected first half of 2026.
- Martin Dewhurst (30+ year McKinsey M&A veteran) appointed to Board of Directors.
- Vaccine pipeline expanded to include intranasal influenza candidate; in-vivo/vitro studies start Q1 2026.
- Commercial partnership with Medline expected to generate near-term revenue in 2026 in wound care.
- Strengthened balance sheet via share purchase agreement extends cash runway into late 2026.

## SEC filing metadata
- accession: 0001213900-26-003153
- form_type: 8-K
- ticker: TTRX
- cik: 0002023016
- company_name: Turn Therapeutics Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2023016/000121390026003153/0001213900-26-003153-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2023016/000121390026003153/ea0272490-8k_turn.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-003153
- JSON: https://secwatch.observer/filing/0001213900-26-003153.json
- Plain text: https://secwatch.observer/filing/0001213900-26-003153.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.